Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 22 for “"Exemestane"”.

  1. Influence of the UGT2B17 Gene on the Relationship Between Exemestane and Bone Mineral Density in Postmenopausal Women

    … (MAP.3) randomized placebo-controlled trial of exemestane, postmenopausal women experienced a loss in bone mineral density (BMD). UGT2B17 facilitates excretion of androgens and exemestane. For Caucasian postmenopausal women, this gene deletion is hypothesized to have 1) a protective effect on …

    queens Repository record for Influence of the UGT2B17 Gene on the Relationship Between Exemestane and Bone Mineral Density in Postmenopausal Women (opens in a new tab)

  2. The associations between estrogens, the UGT2B17 gene deletion, and health-related quality of life in postmenopausal women in the MAP.3 chemoprevention trial

    … quality of life (HRQL). For women taking exemestane in the Mammary Prevention 3 (MAP.3) trial, symptoms may have been exacerbated, as exemestane works to further suppress estrogen levels to prevent breast cancer. Women with the UGT2B17 gene deletion have limited ability to metabolize and …

    queens Repository record for The associations between estrogens, the UGT2B17 gene deletion, and health-related quality of life in postmenopausal women in the MAP.3 chemoprevention trial (opens in a new tab)

  3. The Effect of Exemestane on Menopause-Specific Health-Related Quality of Life and a Comparison With Clinician-Reported Toxicities: an Analysis of the NCIC CTG MAP.2 Chemoprevention Trial

    Background: Exemestane is a drug of great interest for breast cancer prevention, because it inhibits estrogen production. Estrogen may operate by increasing breast density, a well-established biomarker for increased breast cancer risk. The NCIC CTG MAP.2 trial examined the efficacy of exemestane in …

    queens Repository record for The Effect of Exemestane on Menopause-Specific Health-Related Quality of Life and a Comparison With Clinician-Reported Toxicities: an Analysis of the NCIC CTG MAP.2 Chemoprevention Trial (opens in a new tab)

  4. UGT2B17, exemestane metabolism, and their association with physical health-related quality of life in Caucasian postmenopausal women participating in the Mammary Prevention.3 Trial

    … In the Mammary Prevention.3 (MAP.3) trial of exemestane (EXE) for breast cancer prevention, postmenopausal women commonly reported physical menopause-related symptoms, such as joint and muscle pain and fatigue. UGT2B17 contributes to the elimination of EXE-induced activity; however, …

    queens Repository record for UGT2B17, exemestane metabolism, and their association with physical health-related quality of life in Caucasian postmenopausal women participating in the Mammary Prevention.3 Trial (opens in a new tab)

  5. The Association between the UGT2B17 Gene Deletion and Menopause-Related Quality of Life in Postmenopausal Women in the CCTG MAP.3 Breast Cancer Chemoprevention Trial

    … was a randomized placebo controlled trial of exemestane for breast cancer prevention. Participants commonly experienced vasomotor symptoms, such as hot flashes. Exemestane is ultimately eliminated through glucuronidation activity by UGT2B17; approximately 10% of Caucasians are homozygous null …

    queens Repository record for The Association between the UGT2B17 Gene Deletion and Menopause-Related Quality of Life in Postmenopausal Women in the CCTG MAP.3 Breast Cancer Chemoprevention Trial (opens in a new tab)

  6. The Effect of Vaginal Estrogen on Circulating Estrogen and Breast Cancer Risk in Postmenopausal Women Participating in the MAP.3 Breast Cancer Prevention Trial

    … post-randomization (placebo (n=1,682) or exemestane (n=1,544)). VE use was self-reported and annual mammograms recorded breast cancer events. Multiple linear regression modeling was conducted to investigate the association between VE use and serum estrogen at baseline and recent VE use at …

    queens Repository record for The Effect of Vaginal Estrogen on Circulating Estrogen and Breast Cancer Risk in Postmenopausal Women Participating in the MAP.3 Breast Cancer Prevention Trial (opens in a new tab)

  7. Avaliação citológica em base líquida de fármacos moduladores estrogênicos

    … maturation (diestrais), while anastrozole and exemestane increased the duration of the phases of larger maturation (estrais). The data were analysed through a cubical non linear regression (spline) which allowed a better characterization of the drugs, suggesting a proper cytological profile to …

    brazil-ufrn Repository record for Avaliação citológica em base líquida de fármacos moduladores estrogênicos (opens in a new tab)

  8. Examining the Relationship Between Insulin-Like Growth Factor-I and Breast Density in Post-Menopausal Women

    … a clinical trial that analyzed the efficacy of exemestane in reducing breast cancer risk. Cumulus software was used to calculate percent breast density values from provided mammograms. These values were then dichotomized as being either low (< 25%) or moderately high (≥ 25%). IGF-I …

    queens Repository record for Examining the Relationship Between Insulin-Like Growth Factor-I and Breast Density in Post-Menopausal Women (opens in a new tab)

  9. Factors Associated With Worsening Menopause-Specific Health-Related Quality of Life and Treatment Discontinuation in a Breast Cancer Chemoprevention Trial

    … randomized placebo-controlled trial evaluating exemestane for breast cancer prevention demonstrated a 65% relative reduction in invasive breast cancer incidence. Up to 50% of participants in both trial arms reported a clinically meaningful worsening in their menopause-specific health-related …

    queens Repository record for Factors Associated With Worsening Menopause-Specific Health-Related Quality of Life and Treatment Discontinuation in a Breast Cancer Chemoprevention Trial (opens in a new tab)

  10. Vitamin D and mammographic density in postmenopausal women: A cohort study nested within a chemoprevention trial

    … latitudes. Potential effect modification by exemestane therapy, calcium or genetic polymorphisms in the vitamin D pathway was also examined. Methods: This study evaluated a sub-cohort of postmenopausal women at elevated BC risk who participated in the NCIC Clinical Trials Group …

    queens Repository record for Vitamin D and mammographic density in postmenopausal women: A cohort study nested within a chemoprevention trial (opens in a new tab)

  11. Hormonal factors and insulin-like growth factor-1 in North American postmenopausal women

    … 2. Changes in IGF-1 were compared between the exemestane and placebo, and effect modification by BMI was tested with an interaction term. Results: Objective 1. Women aged 55 years or older at menopause had 16.26 ng/mL (95% CI: 1.76, 30.75) higher IGF-1 compared to women aged less than 50 years …

    queens Repository record for Hormonal factors and insulin-like growth factor-1 in North American postmenopausal women (opens in a new tab)

  12. Statistical modelling of biomarkers incorporating non-proportional effects for survival data: with illustration by application to two residual risk models for predicting risk in early breast cancer

    … Series (BCS) and the Tamoxifen versus Exemestane Adjuvant Multinational (TEAM) trial. Similar results were observed between the two approaches that were considered, the multivariable fractional polynomial time (MFPT) approach and Royston-Parmer flexible parametric models, with their …

    edinburgh Repository record for Statistical modelling of biomarkers incorporating non-proportional effects for survival data: with illustration by application to two residual risk models for predicting risk in early breast cancer (opens in a new tab)

  13. A Mechanistic Modeling Framework for Pharmacogenomics-Informed Prediction of Bone Toxicity

    … was used to simulate long-term BMD loss during exemestane treatment, evaluate the impact of denosumab and romosozumab interventions, and examine genetic contributions to heterogeneity in treatment response. The developed model successfully reproduced observed trends in bone loss during aromatase …

    jhu Repository record for A Mechanistic Modeling Framework for Pharmacogenomics-Informed Prediction of Bone Toxicity (opens in a new tab) Embargoed until 2030-08-01

  14. Estrogen’s Impact on the Specialized Transcriptome, Brain, and Vocal Learning Behavior of a Sexually Dimorphic Songbird

    … females. I treated animals with either vehicle, exemestane (an estrogen synthesis inhibitor), or 17-β-estradiol from the moment of hatching until time of sacrifice. I collected the song learning nuclei and their surrounding brain regions during the onset of sensory motor learning for …

    duke Repository record for Estrogen’s Impact on the Specialized Transcriptome, Brain, and Vocal Learning Behavior of a Sexually Dimorphic Songbird (opens in a new tab)

  15. Συστηματική ανασκόπηση της αποτελεσματικότητας και της ασφάλειας του Giredestrant στη θεραπεία του καρκίνου του μαστού - Systematic review on the efficacy and safety of Giredestrant for breast cancer therapy

    … νόσου με giredestrant + everolimus έναντι exemestane + everolimus μετά από πρόοδο υπό CDK4/6-αναστολείς. Τρεις επιπλέον μελέτες φάσης III (lidERA BC, persevERA BC, pionERA BC) βρίσκονται σε εξέλιξη. Το giredestrant ήταν γενικώς καλά ανεκτό, με τις περισσότερες ανεπιθύμητες ενέργειες να …

    athens Repository record for Συστηματική ανασκόπηση της αποτελεσματικότητας και της ασφάλειας του Giredestrant στη θεραπεία του καρκίνου του μαστού - Systematic review on the efficacy and safety of Giredestrant for breast cancer therapy (opens in a new tab)

  16. THE ROLES OF DHEA-S AND AKR1C3 VARIANTS IN AKR1C3-MEDIATED PROSTATE CANCER DRUG RESISTANCE

    … reported major differences in metabolism of exemestane, an aromatase inhibitor used to treat breast cancer, by variants H5Q, E77G, K104D, and R258C compared to WT. To determine if nsSNPs could impact AKR1C3’s role in CRPC, we purified AKR1C3 H5Q, E77G, K104D, and R258C from E. coli to …

    penn Repository record for THE ROLES OF DHEA-S AND AKR1C3 VARIANTS IN AKR1C3-MEDIATED PROSTATE CANCER DRUG RESISTANCE (opens in a new tab)

  17. Aromatase inhibitors produce hypersensitivity in experimental models of pain : studies in vivo and in isolated sensory neurons

    … mg/kg letrozole or daily dosing of letrozole or exemestane in male rats augments flinching behavior induced by intraplantar ATP injection. To determine whether the effects of AIs on nociceptive behaviors are mediated by activation or sensitization of peptidergic sensory neurons, I determined …

    iupui Repository record for Aromatase inhibitors produce hypersensitivity in experimental models of pain : studies in vivo and in isolated sensory neurons (opens in a new tab)

  18. Polymorphisms in the GSTA1 and UGT2B17 genes, estrogen levels and menopause-related side effects among post-menopausal women participating in the MAP.3 trial

    … The Mammary Prevention.3 (MAP.3) trial evaluated exemestane (EXE) for breast cancer prevention, where menopause-related symptoms such as joint pain, fatigue, and hot flashes were common. Genetic variation in detoxification enzyme genes, including GSTA1 and UGT2B17, may influence estrogen …

    queens Repository record for Polymorphisms in the GSTA1 and UGT2B17 genes, estrogen levels and menopause-related side effects among post-menopausal women participating in the MAP.3 trial (opens in a new tab)

  19. Διερεύνηση και κλινική αξιολόγηση νέων δεικτών μεθυλίωσης του DNA στον καρκίνο, στα πλαίσια της υγρής βιοψίας

    … associated with lack of response to everolimus/exemestane treatment. We additionally developed and clinically validated an assay for MLL3 promoter methylation as a novel circulating epigenetic biomarker in non-small cell lung cancer (NSCLC). Our data indicate for the first time that the …

    greece Repository record for Διερεύνηση και κλινική αξιολόγηση νέων δεικτών μεθυλίωσης του DNA στον καρκίνο, στα πλαίσια της υγρής βιοψίας (opens in a new tab)

Page 1 of 2